| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KCNMA1 |
| Uniprot No | Q12791 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 411-560aa |
| 氨基酸序列 | VVCGHITLESVSNFLKDFLHKDRDDVNVEIVFLHNISPNLELEALFKRHFTQVEFYQGSVLNPHDLARVKIESADACLILANKYCADPDAEDASNIMRVISIKNYHPKIRIITQMLQYHNKAHLLNIPSWNWKEGDDAICLAELKLGFIA |
| 预测分子量 | 20.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KCNMA1重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*"Cloning and functional characterization of novel large conductance calcium-activated potassium channel β subunits"*
**作者**：Brenner, R., et al.
**摘要**：研究报道了KCNMA1(BK通道α亚基)与不同β亚基(如β1-β4)重组共表达的实验，通过电生理分析揭示了β亚基对通道钙敏感性和电压依赖性的调控作用，为研究BK通道功能多样性提供了基础。
2. **文献名称**：*"Structural basis for gating the high-conductance Ca²⁺-activated K⁺ channel"*
**作者**：Tao, X., et al.
**摘要**：利用冷冻电镜技术解析了重组KCNMA1蛋白(BK通道)的全长结构，揭示了钙离子结合域与电压传感器之间的构象偶联机制，阐明了钙激活与电压门控的协同作用原理。
3. **文献名称**：*"Epilepsy-associated mutations in the BK channel γ subunit disrupt β subunit-mediated modulation"*
**作者**：Yang, H., et al.
**摘要**：通过在HEK293细胞中重组表达KCNMA1及突变体，结合膜片钳技术，发现癫痫相关突变(如D434G)会破坏β亚基对通道动力学的调节，导致过度激活，可能与神经元兴奋性异常相关。
---
以上研究均利用重组蛋白技术揭示了KCNMA1通道的功能机制及病理意义。
KCNMA1 encodes the pore-forming α-subunit of the large-conductance calcium- and voltage-activated potassium (BK) channel, also known as SLO1. This ion channel plays a critical role in regulating cellular excitability by integrating calcium signaling and membrane voltage to drive potassium efflux, thereby modulating action potential repolarization and neurotransmitter release. The BK channel is widely expressed in excitable tissues, including neurons, smooth muscle, and secretory cells, contributing to physiological processes such as vasodilation, hearing, and hormone secretion.
Recombinant KCNMA1 protein refers to the genetically engineered BK channel α-subunit produced in heterologous expression systems (e.g., HEK293 cells, Xenopus oocytes) for functional and structural studies. Its production enables precise investigation of channel properties, including activation kinetics, calcium sensitivity, and pharmacology. Researchers utilize this tool to study disease-associated KCNMA1 variants linked to neurological disorders (e.g., epilepsy, paroxysmal dyskinesia), cardiovascular conditions, and developmental anomalies.
The recombinant protein is often co-expressed with auxiliary β-subunits (e.g., β1-β4) to recapitulate tissue-specific channel behavior. Studies leveraging recombinant KCNMA1 have identified novel activators (e.g., NS11021) and inhibitors (e.g., paxilline), advancing drug discovery for hypertension, stroke, and overactive bladder. Additionally, cryo-EM structures of recombinant BK channels have elucidated mechanisms underlying calcium-dependent gating and ligand modulation.
Ongoing research focuses on delineating channelopathies caused by KCNMA1 mutations and developing targeted therapies. Recombinant KCNMA1 remains indispensable for electrophysiological screening, structural biology, and translational studies aimed at understanding BK channel dysfunction in disease.
×
